[go: up one dir, main page]

PE20081406A1 - Composiciones farmaceuticas de flunixina - Google Patents

Composiciones farmaceuticas de flunixina

Info

Publication number
PE20081406A1
PE20081406A1 PE2007001807A PE2007001807A PE20081406A1 PE 20081406 A1 PE20081406 A1 PE 20081406A1 PE 2007001807 A PE2007001807 A PE 2007001807A PE 2007001807 A PE2007001807 A PE 2007001807A PE 20081406 A1 PE20081406 A1 PE 20081406A1
Authority
PE
Peru
Prior art keywords
improver
flunixin
pharmaceutical compositions
primary
penetration
Prior art date
Application number
PE2007001807A
Other languages
English (en)
Inventor
Cheyney Meadows
Keith Alan Freehauf
Robert D Simmons
Allan J Weingarten
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of PE20081406A1 publication Critical patent/PE20081406A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UNA PREPARACION LIQUIDA TRANSDERMICA QUE COMPRENDE: a) UN PRIMER Y UN SEGUNDO MEJORADOR DE LA PENETRACION DERMICA, b) UN SOLVENTE PRIMARIO APROTICO Y c) FLUNIXINA O UNA SAL DE LA MISMA TAL COMO MEGLUMINA, DONDE EL PRIMER MEJORADOR DE LA PENETRACION ES ALCANFOR, MENTOL, NEROLIDOL, ENTRE OTROS; EL SEGUNDO MEJORADOR ES XILENO, D-LIMONENO, ACIDO DECANOICO, ENTRE OTROS; EL SOLVENTE PRIMARIO APROTICO ES PIRROLIDONA, N,N-DIMETILACETAMIDA, ACETONA, ENTRE OTROS. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS EN ANIMALES, PARTICULARMENTE, MAMIFEROS TALES COMO VACAS
PE2007001807A 2006-12-20 2007-12-14 Composiciones farmaceuticas de flunixina PE20081406A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87090706P 2006-12-20 2006-12-20

Publications (1)

Publication Number Publication Date
PE20081406A1 true PE20081406A1 (es) 2008-10-17

Family

ID=39262615

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001807A PE20081406A1 (es) 2006-12-20 2007-12-14 Composiciones farmaceuticas de flunixina

Country Status (19)

Country Link
US (1) US9006272B2 (es)
EP (1) EP2120860B1 (es)
JP (1) JP5377326B2 (es)
KR (1) KR20090091328A (es)
CN (2) CN101588789B (es)
AR (1) AR064425A1 (es)
AU (1) AU2007339312B2 (es)
BR (1) BRPI0720500B1 (es)
CA (1) CA2672964C (es)
CL (1) CL2007003711A1 (es)
CO (1) CO6190598A2 (es)
ES (1) ES2714550T3 (es)
MX (1) MX2009006893A (es)
NZ (1) NZ598554A (es)
PE (1) PE20081406A1 (es)
RU (1) RU2466715C2 (es)
TW (1) TWI350182B (es)
WO (1) WO2008082507A2 (es)
ZA (1) ZA200904329B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2738970A1 (en) * 2008-10-31 2010-05-06 Moberg Derma Ab Topical composition comprising a combination of at least two penetration enhancing agents
CA2828086C (en) * 2010-03-10 2018-07-31 Nuvo Research Inc. Foamable formulation
WO2012022837A1 (en) * 2010-08-16 2012-02-23 Helsingin Yliopisto Transdermal compositions
RU2576612C2 (ru) * 2010-09-30 2016-03-10 Тояма Кемикал Ко., Лтд. Трансдермальный абсорбируемый препарат
CA2902282C (en) * 2013-02-27 2023-03-14 Laurie Robert BATT Transdermal formulations
CN105769827B (zh) * 2016-03-09 2018-07-17 金陵科技学院 用于动物清热镇痛氟尼辛葡甲胺涂膜剂及其制备方法
KR20200065711A (ko) 2018-11-30 2020-06-09 한원경 동물 피부질환 개선용 조성물
EP3999032A4 (en) 2019-07-16 2023-08-30 Donaghys Limited Transdermal solvent system and methods of use
US11419876B2 (en) 2019-09-06 2022-08-23 Iowa State University Research Foundation, Inc. Mirtazapine as a pre-shipping inhibitor of bovine respiratory disease
WO2022112277A1 (en) * 2020-11-25 2022-06-02 Intervet International B.V. Method of treatment of pain through buccal administration of flunixin
WO2022238965A1 (en) * 2021-05-12 2022-11-17 Argenta Innovation Limited Veterinary transdermal formulation
CN114404360B (zh) * 2021-12-16 2023-03-28 江西益昕葆生物科技有限公司 一种氟尼辛葡甲胺注射液的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63225316A (ja) * 1986-10-21 1988-09-20 Nitto Electric Ind Co Ltd 外皮投与用組成物
JPH11222443A (ja) * 1997-11-11 1999-08-17 Saitama Daiichi Seiyaku Kk 経皮吸収促進組成物および経皮吸収製剤
CN100409847C (zh) * 1999-11-19 2008-08-13 美国爱科赛尔制药有限公司 乌头属生物碱经皮给药系统
JP4865958B2 (ja) * 2001-05-23 2012-02-01 株式会社トクホン 鎮痛抗炎症局所作用型の貼付剤
US6790867B2 (en) * 2002-05-20 2004-09-14 Schering-Plough Animal Health Corporation Compositions and method for treating infection in cattle and swine
CA2530407A1 (en) * 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
KR100780983B1 (ko) * 2003-07-31 2007-11-30 파마시아 앤드 업존 캄파니 엘엘씨 소염제의 분산성 제제
DE10358525A1 (de) * 2003-12-13 2005-07-07 Bayer Healthcare Ag Endoparasitizide Mittel zur topischen Applikation
US7618651B2 (en) * 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
KR100867246B1 (ko) * 2004-07-19 2008-11-10 워너-램버트 캄파니 엘엘씨 모발 성장 촉진용 제제
JP2008513388A (ja) * 2004-09-16 2008-05-01 バイエル・ヘルスケア・アクチェンゲゼルシャフト 動物の皮膚病を処置するための皮膚投与可能な製剤
WO2007061739A2 (en) * 2005-11-21 2007-05-31 Schering-Plough Ltd. Pharmaceutical compositions comprising buprenorphine

Also Published As

Publication number Publication date
JP2010513500A (ja) 2010-04-30
BRPI0720500A8 (pt) 2015-12-29
CN101588789B (zh) 2013-12-11
RU2009127500A (ru) 2011-01-27
CN101588789A (zh) 2009-11-25
RU2466715C2 (ru) 2012-11-20
WO2008082507A3 (en) 2009-03-19
AR064425A1 (es) 2009-04-01
JP5377326B2 (ja) 2013-12-25
BRPI0720500B1 (pt) 2019-01-02
WO2008082507A2 (en) 2008-07-10
CL2007003711A1 (es) 2008-07-25
MX2009006893A (es) 2009-07-03
CA2672964C (en) 2018-04-03
TWI350182B (en) 2011-10-11
CN103690471B (zh) 2015-11-18
AU2007339312B2 (en) 2013-06-06
EP2120860A2 (en) 2009-11-25
CO6190598A2 (es) 2010-08-19
ES2714550T3 (es) 2019-05-29
BRPI0720500A2 (pt) 2014-02-04
NZ598554A (en) 2013-08-30
US9006272B2 (en) 2015-04-14
KR20090091328A (ko) 2009-08-27
EP2120860B1 (en) 2019-01-23
ZA200904329B (en) 2010-05-26
AU2007339312A1 (en) 2008-07-10
US20080153885A1 (en) 2008-06-26
CA2672964A1 (en) 2008-07-10
CN103690471A (zh) 2014-04-02
TW200833367A (en) 2008-08-16

Similar Documents

Publication Publication Date Title
PE20081406A1 (es) Composiciones farmaceuticas de flunixina
AR116415A2 (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
BR112015019657A2 (pt) composições tópicas e métodos de uso das mesmas
MX2020001395A (es) Composiciones y su uso para suministro de iduronato-2-sulfatasa al sistema nervioso central.
CO6311008A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
UY32761A (es) Preparaciones termoestables y preparaciones insulinicas estables a las vibraciones
CO6710926A2 (es) Compuestos de n-heteroarilo
WO2008057930A3 (en) Methods of treating neuropathic pain with retinoic acid receptor agonists
BR112012015433B8 (pt) composição farmacêutica substancialmente anidra para aplicação cutânea
CL2011000144A1 (es) Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros.
TR200806298A2 (tr) Farmasötik formülasyon
AR072685A1 (es) Composicion topica para el tratamiento de queratosis actinica
BR112012015437A2 (pt) composição tópica substancialmente anidra de armazenamento estável
NI201000189A (es) Formulación de medicamento sólido con liberación retardadas.
AR080736A1 (es) Composicion farmaceutica de disolucion rapida, usualmente bucodispersable, y proceso para prepararla
BR112015020707A2 (pt) formulações transdermicas
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
BR112014016661A8 (pt) formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma
BR112013031146A2 (pt) liberação direcionada de compostos retinóides para as glândulas sebáceas
CL2008001563A1 (es) Compuestos derivados de benzodioxanos condensados con heterociclos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, crisis de panico, entre otras.
ECSP10010183A (es) Producto de dispersión sólida de drogas basadas en n-aril-urea
BR112017017643A2 (pt) formulação farmacêutica tópica
AR051429A1 (es) Composicion farmaceutica ozonizada y metodos para obtenerla
EA200701228A1 (ru) Стабильные композиции фенофибрата с эфирами жирных кислот

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed